A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

BACKGROUND: There is an unmet need to identify novel predictive biomarkers that enable more accurate identification of individuals who can benefit from immune checkpoint inhibitor (ICI) therapy. The US FDA recently approved tumor mutational burden (TMB) score of ≥ 10 mut/Mb as a threshold for pembro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xilin, Guo, Jing, Shi, Jianguang, Li, Da, Li, Xinjian, Zhao, Weijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288780/
https://www.ncbi.nlm.nih.gov/pubmed/37349743
http://dx.doi.org/10.1186/s12890-023-02512-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288780/
https://www.ncbi.nlm.nih.gov/pubmed/37349743
http://dx.doi.org/10.1186/s12890-023-02512-6

Ejemplares similares